title: Two-locus involvement in the association of human leukocyte antigen with the extrahepatic manifestations of autoimmune chronic active hepatitis.
abstract: We investigated the association of human leukocyte antigen antigens and type 1 chronic active "autoimmune" hepatitis in a population of 65 white Argentinian patients, taking into account the different manifestations of the disease. Standard microlymphocytotoxicity was used for human leukocyte antigen A, B, C, DR and DQ typing. Human leukocyte antigen class 2 alleles were also typed on genomic DNA by means of polymerase chain reaction amplification and hybridization to sequence specific oligonucleotides. A primary association with human leukocyte antigen DR4 was present (human leukocyte antigen DR4: 44% in patients vs. 29% in controls; chi 2, 5.6; p = 0.02, relative risk, 2.1). However, a novel association was observed with human leukocyte antigen A11 (31% in patients vs. 6% in the controls; chi 2, 25.3; corrected p = 0.001; relative risk, 6.8). Moreover, of the 20 human leukocyte antigen A11 patients, 18 had extrahepatic manifestations associated with autoimmune chronic active hepatitis. This represented 60% of the patients bearing this form of the disease (n = 30), conferring a relative risk of 22.2 (chi 2, 46.3; corrected p = 0.00008). In this group, human leukocyte antigen DR3 and DR4 had a weak association. When present together, human leukocyte antigen DR4 and human leukocyte antigen A11 had a synergistic effect, yielding an odds ratio of 357. Statistical analysis and family segregation studies suggest that the two loci products may represent independent risk factors for this form of autoimmune chronic active hepatitis. This synergistic effect was not evident with A11 plus DR3. In autoimmune chronic active hepatitis patients without extrahepatic manifestations, a weak association with human leukocyte antigen DR6 was found.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Laboratorio de Immunogenética, Hospital de Clinicas, Universidad de Buenos Aires, Argentina.
authors.forename: Y
authors.initials: Y
authors.lastname: Marcos
authors.forename: H A
authors.initials: HA
authors.lastname: Fainboim
authors.forename: M
authors.initials: M
authors.lastname: Capucchio
authors.forename: J
authors.initials: J
authors.lastname: Findor
authors.forename: J
authors.initials: J
authors.lastname: Daruich
authors.forename: B
authors.initials: B
authors.lastname: Reyes
authors.forename: M
authors.initials: M
authors.lastname: Pando
authors.forename: G C
authors.initials: GC
authors.lastname: Theiler
authors.forename: N
authors.initials: N
authors.lastname: Méndez
authors.forename: M L
authors.initials: ML
authors.lastname: Satz
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000483:Alleles; D001118:Argentina / Q000453:epidemiology; D001327:Autoimmune Diseases / Q000453:epidemiology / Q000235:genetics / Q000276:immunology*; D016009:Chi-Square Distribution; D005260:Female; D005500:Follow-Up Studies; D005787:Gene Frequency; D020022:Genetic Predisposition to Disease; D006680:HLA Antigens / Q000097:blood* / Q000145:classification / Q000235:genetics; D006521:Hepatitis, Chronic / Q000453:epidemiology / Q000235:genetics / Q000276:immunology*; D006801:Humans; D008297:Male; D008875:Middle Aged; D016017:Odds Ratio; D012307:Risk Factors
chemical_list: D006680:HLA Antigens